Neutrophil-lymphocyte ratio predicts survival in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD): Stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601

Simple item page
dc.conference.dateSEP 16-21, 2021
dc.conference.titleCongress of the European-Society-for-Medical-Oncology (ESMO)
dc.contributor.authorPerez Fidalgo, J. A.
dc.contributor.authorCortes, A.
dc.contributor.authorGarcia, Y.
dc.contributor.authorIglesias, M.
dc.contributor.authorBohn Sarmiento, U.
dc.contributor.authorCalvo Garcia, E.
dc.contributor.authorManso, L.
dc.contributor.authorSantaballa, A.
dc.contributor.authorOaknin, A.
dc.contributor.authorRedondo, A.
dc.contributor.authorRubio, M. J.
dc.contributor.authorGonzalez-Martin, A.
dc.contributor.authoraffiliation[Perez Fidalgo, J. A.] Hosp Clin Univ Valencia, Dept Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Cortes, A.] Hosp Univ Ramon y Cajal, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Garcia, Y.] Univ Autonoma Barcelona, Inst Invest & Innovacio Parc Tauli I3PT, Parc Tauli Hosp Univ, Dept Med Oncol, Sabadell, Spain
dc.contributor.authoraffiliation[Iglesias, M.] Hosp Son Llatzer, Dept Med Oncol, Palma De Mallorca, Spain
dc.contributor.authoraffiliation[Bohn Sarmiento, U.] Hosp Univ Gran Canaria Dr Negrin, Dept Med Oncol, Las Palmas Gran Canaria, Canary Island, Spain
dc.contributor.authoraffiliation[Calvo Garcia, E.] Hosp Univ Virgen del Rocio, Dept Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Manso, L.] Hosp Univ 12 Octubre, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Santaballa, A.] Hosp Univ & Politecn La Fe, Dept Med Oncol, Valencia, Spain
dc.contributor.authoraffiliation[Oaknin, A.] Hosp Univ Vall dHebron, Vall dHebron Inst Oncol VHIO, Dept Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Redondo, A.] Hosp Univ La Paz IdiPAZ, Dept Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Rubio, M. J.] Hosp Univ Reina Sofia, Dept Med Oncol, Cordoba, Spain
dc.contributor.authoraffiliation[Gonzalez-Martin, A.] Clin Univ Navarra, Dept Med Oncol, Madrid, Spain
dc.contributor.funderAstraZeneca
dc.date.accessioned2025-01-07T13:50:21Z
dc.date.available2025-01-07T13:50:21Z
dc.date.issued2021-09-21
dc.identifier.doi10.1016/j.annonc.2021.08.1177
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.annonc.2021.08.1177
dc.identifier.urihttps://hdl.handle.net/10668/25899
dc.identifier.wosID700527701201
dc.issue.number5
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS735-S735
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleNeutrophil-lymphocyte ratio predicts survival in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD): Stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number32
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Reina Sofía
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía